Applications of 2',3'-O-Isopropylideneuridine in Industrial Manufacturing

2',3'-O-Isopropylideneuridine plays a vital role as a protected nucleoside intermediate, widely utilized in the industrial synthesis of advanced nucleotide derivatives. Our manufacturing expertise ensures consistent quality for complex downstream processes. Below we highlight authentic application scenarios where downstream partners incorporate this intermediate into specific processes, meeting rigorous global standards and production demands.

1. Antiviral Nucleoside Analog Synthesis

Pharmaceutical companies leverage this protected uridine derivative during multi-step synthesis of antiviral nucleoside analogs, minimizing undesirable side reactions. Its use as a selectively protected intermediate facilitates high-yield coupling and subsequent deprotection steps in the scalable production of active pharmaceutical ingredients (APIs) targeting viral infections, such as hepatitis and HIV.

Industry compliance standards

• USP General Chapter <825> for compounding nucleoside analog APIs
• ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients)
• European Pharmacopoeia Monograph 5.10 (Nucleoside derivatives)
• US FDA 21 CFR Part 211 (Current Good Manufacturing Practice for Finished Pharmaceuticals)

Typical usage ratio

• Commonly 1.05–1.20 molar equivalents per uridine step, adjusted by target analog and desired yield in pathway; excess regulated to minimize downstream purification burden.

Downstream process integration

• Introduced during the protection phase ahead of glycosylation or phosphorylation;
• Deprotection timed post-modification to release free uridine function for subsequent functionalization or coupling.

Final product types

• Anti-HIV drugs (e.g., stavudine precursor synthesis)
• Hepatitis B nucleoside analogs (e.g., lamivudine intermediates)
• Nucleoside-based prodrugs for cytostatic or immunosuppressive applications

2. DNA & RNA Oligonucleotide Building Block Preparation

Contract development and manufacturing organizations (CDMOs) employ this protected nucleoside during solid-phase oligonucleotide synthesis, crucial for constructing custom RNA and DNA strands with specific base modifications. It provides the necessary protection to the 2’ and 3’ hydroxyl groups, enabling selective reactions at the 5’ position without cyclic byproduct formation, supporting high-fidelity oligo assembly for therapeutics and research reagents.

Industry compliance standards

• ISO 13485 (Medical Devices—Quality Management Systems)
• ISO 9001 (Quality Management Systems for Oligo Synthesis)
• US FDA CFR Title 21 Part 820 (Quality System Regulation)
• Pharmacopoeia References: USP Monograph on Oligonucleotide Therapeutics

Typical usage ratio

• Stoichiometric amounts: 1.0 molar equivalent matched to each nucleoside position requiring 2’,3’-protection; adjusted case-by-case based on strand length and modification pattern.

Downstream process integration

• Entered during precursor nucleoside functionalization before phosphoramidite or solid-linker attachment
• Deprotected at the final step of oligonucleotide cleavage and purification

Final product types

• Antisense RNA and DNA oligos for gene regulation
• Therapeutic aptamers
• Diagnostic molecular probes
• Custom PCR primers and siRNA constructs

3. Modified Sugar Synthesis for Nucleoside Pharmaceuticals

Specialty chemical producers utilize this protected intermediate for the route-selective synthesis of modified ribose sugars in nucleoside-based drugs. Its acetonide group provides essential masking of reactive hydroxyls, ensuring controlled regioselective transformations, such as halogenation or methylation, to produce rare sugar derivatives further used in second-generation nucleotide analogs.

Industry compliance standards

• EU GMP Directive 2003/94/EC
• Japan PMDA Guidelines for Starting Material Synthesis
• ICH Q11 (Development and Manufacture of Drug Substances)
• REACH Registration for Chemical Intermediates (EC/1907/2006)

Typical usage ratio

• Typically 0.95–1.10 molar equivalents to free ribose or corresponding nucleoside; ratio tuned based on scale of batch and process selectivity targets.

Downstream process integration

• Reacted at early-stage sugar protection before stepwise introduction of base modifications
• Acts as a transient protecting group, removed post-modification to yield desired sugar isomer

Final product types

• Fluorinated nucleoside precursors
• Azido-sugar nucleotides
• Dideoxynucleoside drug intermediates

4. Nucleotide Prodrug Intermediate Manufacturing

Several large-scale active pharmaceutical ingredient (API) producers opt for this protected uridine derivative to streamline prodrug synthesis, where masking groups control sequential chemical transformations. The isopropylidene moiety temporarily shelters the ribose diols during esterification or phosphorylation, supporting high selectivity in synthesizing nucleoside phosphoramidates deployed as improved oral agents in antiviral and anticancer therapy.

Industry compliance standards

• US FDA DMF (Drug Master File) Requirements for Intermediate Control
• ICH Q6A (Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products)
• WHO GMP for Pharmaceutical Intermediates
• EudraLex Vol. 4 Annex 2 (EU Guidelines for the Manufacture of Active Substances)

Typical usage ratio

• Ranges between 1.0–1.15 equivalents per protected nucleoside, with ratio influenced by extent of conversion needed in specific prodrug moiety attachment routes.

Downstream process integration

• Applied in pre-functionalization steps for site-selective phosphorylation
• Deprotection commonly synchronized with ester or amidate cleavage for final API isolation

Final product types

• Nucleoside phosphoramidate prodrugs (e.g., NRTI prodrugs for hepatitis C)
• Lipid-conjugated nucleoside therapeutics
• Oral bioavailable antiviral and anticancer agents

5. Research-Grade Nucleotide Derivative Synthesis

Academic and industrial laboratories source this compound for the preparation of research nucleotides, modified uridine analogs, and custom building blocks. Its selective protection enables the controlled study and development of novel nucleotide analogs assessed for enzymatic activity, molecular biology applications, or structure-activity relationship exploration.

Industry compliance standards

• ISO/IEC 17025 (Testing and Calibration Laboratories Requirements)
• GLP (Good Laboratory Practice) for Non-Clinical R&D
• NIH Guidelines for Chemical Handling in Research
• OECD Principles of Good Laboratory Practice

Typical usage ratio

• Practice typically prescribes 1.0–1.2 molar equivalents, with minor adjustments for experimental syntheses and pilot batch optimization.

Downstream process integration

• Inserted at initial synthetic steps to temporarily mask 2’,3’-hydroxyls in experimental uridine derivatives
• Protection removed in final analytical or assay-ready stages

Final product types

• Custom-labeled nucleotides (e.g., biotinylated, fluorescently tagged)
• Enzyme substrate probes for polymerase research
• Structure-activity relationship (SAR) uridine derivatives